Journal article

Hepatitis B surface antigen quantification: Why and how to use it in 2011-A core group report

Henry Lik-Yuen Chan, Alex Thompson, Michelle Martinot-Peignoux, Teerha Piratvisuth, Markus Cornberg, Maurizia Rossana Brunetto, Hans L Tillmann, Jia-Horng Kao, Ji-Dong Jia, Heiner Wedemeyer, Stephen Locarnini, Harry LA Janssen, Patrick Marcellin



Quantitative HBsAg had been suggested to be helpful in management of HBV, but assays were cumbersome. The recent availability of commercial quantitative assays has restarted the interest in quantitative serum hepatitis B surface antigen (HBsAg) as a biomarker for prognosis and treatment response in chronic hepatitis B. HBsAg level reflects the transcriptional activity of cccDNA rather than the absolute amount of cccDNA copies. Serum HBsAg level tends to be higher in hepatitis B e antigen (HBeAg)-positive than HBeAg-negative patients. Among patients with a low HBV DNA (<2000IU/ml), HBsAg <1000IU/ml in genotype D HBV infection and HBsAg <100IU/ml in genotype B/C HBV infection is associated wit..

View full abstract


Funding Acknowledgements

H.L.Y.C. is a consultant and advisor of Abbott, Bristol Myers Squibb, F. Hoffmann-la Roche, Merck and Novartis Pharmaceutical. A.T. has served as an advisor to Merck, Roche, Gilead and Janssen-Cilag and has received speaker's fees from Merck and Roche. T.P. served on the advisory board and is on the speaker bureaus for Roche, Schering-Plough Corporation, Novartis, GlaxoSmithKline and Bristol-Myers Squibb. M.C. received lecture fees and/or consult fees from GlaxoSmithKline, Gilead, Novartis, Bristol-Myers-Squibb, Roche, and Merck. M.R.B. is speaker bureau/advisor of Abbott, BMS, Gilead, Hoffmannla Roche and Merck. H.L.T. received travel support, lecturer fees, grants and consultant fees by Novartis, Roche and/or Abbott, and his wife is an employee of Abbott and holds also stocks in Abbott. J.H.K. is a consultant and advisor of Abbott, Bristol Myers Squibb, GlaxoSmithKline, Merck, Novartis, Omrix, and F Hoffmann-la Roche. J.D.J. is an advisory board member of Bristol Myers Squibb, Glaxo-Smith-Kline, Novartis Pharmaceutical, Merck, and Roche China. H.W. received lecturer/consultant fees, and grant support from Abbott, BMS, Gilead, Merck, Novartis, and Roche. H.L.A.J. received grants from and is consultant for Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, and Merck. P.M. is a consultant for, and is on the speakers' bureau of Roche, Schering-Plough, Gilead, Bristol-Myers Squibb, GlaxoSmithKline, and Idenix-Novartis; a consultant for and advises Vertex, Valeant, Human Genome Sciences, Cythesis, Intermune, Wyeth, and Tibotec; and an advisor for Coley Pharma. M.M.P. and S.L. reported no potential conflict of interest.